REPLAY NEWS · in brief
TOUS 4622 Moderna obtient le feu vert americain pour son premier vaccin antigrippal a ARN messager
The U.S. Food and Drug Administration has authorized the first seasonal flu vaccine using messenger RNA (mRNA) technology developed by Moderna. Called mFlusiva, this serum marks a new milestone for this technology after its use against COVID-19. Intended primarily for adults over 50, it could allow for faster adaptation to evolving flu viruses thanks to a more flexible design than traditional vaccines.
© REPLAY NEWS — All rights reserved. Substantial reproduction requires permission.